Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SynOV1.1
- Development stage
- Phase 1
- Lead developer
- Beijing Syngentech
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Recombinant Proteins and Enzymes, Gene Therapies
- Administration
- Intratumoral, Intravenous, Intra-arterial
01
Overview
SynOV1.1 is an investigational cancer immunotherapy developed by Beijing SyngenTech. It is a recombinant oncolytic adenovirus engineered to selectively replicate in tumor cells, particularly those expressing alpha-fetoprotein (AFP), using an enhanced AFP promoter for tumor specificity[6][2]. SynOV1.1 encodes human granulocyte-macrophage colony-stimulating factor (GM-CSF), which stimulates anti-tumor immune responses by recruiting and activating immune cells within the tumor microenvironment[2][6]. The therapy aims to induce direct lysis of cancer cells and enhance systemic anti-tumor immunity, with primary indications in advanced or metastatic solid tumors, including late-stage liver cancer[5][3].
- Other names
- recombinant human GM-CSF-encoding oncolytic adenovirus synov1.1
02
Targets
CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)CXADR (Coxsackievirus and adenovirus receptor)
Beyond the preview
Go deeper on SynOV1.1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SynOV1.1.